NaviFUS

NaviFUS P/B

The P/B (Price-to-Book Ratio) of NaviFUS (6872.TWO) as of Nov 4, 2026 is 2.51. In the previous year, P/B (Price-to-Book Ratio) was 2.89 — a change of -13.34% (lower).

P/B

2.51

YoY

-13.34%

Last updated:

P/B (Price-to-Book Ratio) of NaviFUS is 2025 2.51 . P/B (Price-to-Book Ratio) of NaviFUS was 2024 2.89 . It decreases by -13.34% lower compared to the previous year.

The NaviFUS P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
5.86 TWD
Jan 1, 2020
4.26 TWD
Jan 1, 2021
2.55 TWD
Jan 1, 2022
2.87 TWD
Jan 1, 2023
3.30 TWD
Jan 1, 2024
2.89 TWD
Jan 1, 2025
2.51 TWD
The NaviFUS P/B history
YEARP/BYoY
2.51-13.34%
2.89-12.15%
3.30+14.65%
2.87+12.68%
2.55-40.13%
4.26-27.28%
5.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NaviFUS Stock analysis

What does NaviFUS do? NaviFUS Corp, listed on the Taiwan Stock Exchange under ticker 6872.TWO with ISIN TW0006872005, is a health care company headquartered in Taipei City, Taiwan. The company went public on June 22, 2022. NaviFUS Corp operates as a medical device company specializing in the development of two core technology platforms: focused ultrasound systems and therapeutic guidance tracking systems. The firm's focus includes the development of medical systems targeting recurrent brain tumors and Alzheimer's disease. The company's website is https://navifus.com/. NaviFUS Corp is engaged in the health care sector, specifically within the health care industry. The company's operations are centered on advancing medical technologies for neurological conditions, with an emphasis on non-invasive treatment approaches. While the company's specific products and market presence are not detailed in the provided information, its technological focus suggests a commitment to innovative solutions in neurology and neurosurgery. The firm's public listing in 2022 marks its transition into a publicly traded entity, reflecting its growth and development in the medical device sector. NaviFUS Corp's headquarters in Taipei City positions it within Taiwan's growing health care technology landscape, contributing to regional advancements in medical innovation. NaviFUS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NaviFUS stock

P/B (Price-to-Book Ratio) of NaviFUS is 2.51 in 2025.

P/B (Price-to-Book Ratio) of NaviFUS changed from 2.89 to 2.51, representing a -13.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) NaviFUS since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s NaviFUS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — NaviFUS

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — NaviFUS